ITCI: Intra-Cellular Therapies, Inc.
About
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in Bedminster, NJ.
Current Value
$83.351 Year Return
Current Value
$83.351 Year Return
Key Details
Market Cap
$8.84B
P/E Ratio
-96.97
1Y Stock Return
42.41%
1Y Revenue Growth
46.08%
Dividend Yield
0.00%
Price to Book
7.7
Strategies that include ITCI
Stock's related to ITCI
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| DAWN | 36.64% | $1.36B | +13.42% | 0.00% |
| AXSM | 34.55% | $4.63B | +61.30% | 0.00% |
| BCRX | 33.39% | $1.49B | +41.37% | 0.00% |
| DRS | 32.74% | $9.28B | +88.06% | 0.00% |
| BRSP | 32.38% | $806.64M | -3.86% | 12.20% |
| RCKT | 32.25% | $1.20B | -39.83% | 0.00% |
| BPMC | 32.11% | $6.01B | +42.68% | 0.00% |
| FOLD | 31.96% | $2.84B | -11.52% | 0.00% |
| ATXS | 31.58% | $550.23M | +114.29% | 0.00% |
| SMP | 30.20% | $690.97M | -10.09% | 3.65% |
| HRMY | 29.52% | $1.85B | +18.24% | 0.00% |
| ATRC | 29.34% | $1.77B | -12.85% | 0.00% |
| ACAD | 29.30% | $2.70B | -27.80% | 0.00% |
| NRDS | 28.62% | $984.08M | +21.93% | 0.00% |
| AVDL | 28.51% | $1.03B | -3.16% | 0.00% |
| EVER | 28.45% | $664.25M | +124.76% | 0.00% |
| SWTX | 28.43% | $2.82B | +79.34% | 0.00% |
| IMVT | 28.33% | $3.70B | -23.48% | 0.00% |
| RVMD | 28.31% | $9.50B | +171.62% | 0.00% |
| PGEN | 28.09% | $228.91M | -28.00% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| IDT | 0.02% | $1.26B | +74.67% | 0.30% |
| MKC | 0.03% | $20.21B | +15.19% | 2.23% |
| DLNG | -0.13% | $161.93M | +73.23% | 0.00% |
| KEP | 0.14% | $11.16B | +25.58% | 0.00% |
| TLK | 0.21% | $16.88B | -27.18% | 6.58% |
| AMED | 0.22% | $2.95B | -3.95% | 0.00% |
| KGS | 0.23% | $3.37B | +110.22% | 4.11% |
| THS | 0.23% | $1.72B | -17.36% | 0.00% |
| RPRX | 0.26% | $11.56B | -3.67% | 3.22% |
| ETR | -0.28% | $32.14B | +49.00% | 3.05% |
| CMS | 0.32% | $20.49B | +20.66% | 3.01% |
| CHRW | -0.37% | $12.89B | +32.52% | 2.24% |
| UTI | -0.39% | $1.07B | +73.54% | 0.00% |
| TR | 0.47% | $2.33B | -0.74% | 1.10% |
| AEP | 0.51% | $51.50B | +23.91% | 3.71% |
| CPSH | 0.51% | $20.70M | -40.13% | 0.00% |
| MATX | -0.54% | $5.07B | +59.09% | 0.86% |
| DKL | 0.56% | $2.03B | -18.84% | 10.94% |
| GRAL | 0.60% | $459.22M | -13.00% | 0.00% |
| MFG | 0.63% | $63.12B | +43.52% | 1.44% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| HUSA | -17.22% | $16.69M | -11.56% | 0.00% |
| CRTO | -14.85% | $2.10B | +58.23% | 0.00% |
| CHE | -13.75% | $8.20B | -5.60% | 0.33% |
| BNED | -13.05% | $277.22M | -91.94% | 0.00% |
| LLYVK | -12.85% | $6.24B | +94.65% | 0.00% |
| PRPO | -12.68% | $9.10M | -13.65% | 0.00% |
| LLYVA | -12.10% | $6.11B | +96.84% | 0.00% |
| AIFU | -10.75% | $67.49M | -83.02% | 0.00% |
| CME | -10.61% | $82.76B | +9.21% | 1.98% |
| SRE | -10.30% | $59.15B | +28.15% | 2.62% |
| OXBR | -10.30% | $19.05M | +178.18% | 0.00% |
| ZH | -9.98% | $333.09M | -40.59% | 0.00% |
| PACB | -9.64% | $471.05M | -79.23% | 0.00% |
| NTES | -9.07% | $53.33B | -26.44% | 2.91% |
| DT | -8.99% | $15.40B | -1.30% | 0.00% |
| ZTO | -8.73% | $12.58B | -4.71% | 4.73% |
| KNOP | -8.63% | $210.40M | +11.75% | 1.68% |
| IBKR | -8.58% | $20.20B | +131.83% | 0.37% |
| LYV | -8.19% | $31.00B | +54.46% | 0.00% |
| FE | -7.64% | $23.96B | +10.41% | 4.05% |
ETF's related to ITCI
News
Yahoo
BEDMINSTER, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at three upcoming investor conferences: Evercore 7th Annual HealthCONx ConferenceTuesday, December 3, 2024 at 10:50 a.m. ET in Miami, FL Citi 2024 Global Health
Yahoo
Presentations include results from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) Results show robust efficacy and favorable safety and tolerability profile for CAPLYTA BEDMINSTER, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous sys
Yahoo
The FDA-approved schizophrenia and bipolar disorder therapy met the primary and secondary endpoint in a Phase III “withdrawal trial”.
Yahoo
The efficacy and safety of CAPLYTA (lumateperone) as a maintenance treatment in adults with schizophrenia was demonstrated in a randomized withdrawal trial The study demonstrated a statistically significant (p=0.0002) longer time to relapse in schizophrenia patients treated with lumateperone compared to placebo BEDMINSTER, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeu
Finnhub
Intra-Cellular Therapies, Inc. , a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders, today announced positive results...
Yahoo
It's been a pretty great week for Intra-Cellular Therapies, Inc. ( NASDAQ:ITCI ) shareholders, with its shares surging...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.